UroGen Pharma Announced Topline Data From Phase 3 Trials ATLAS And ENVISION Studying UGN-102 For Intravesical Solution In Patients With Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer; Both Trials Met Primary Endpoints
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma announced positive topline data from Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer. Both trials met primary endpoints, with ATLAS showing a 55% reduction of risk for recurrence, progression or death in patients who received UGN-102, and ENVISION showing a complete response rate of 79.2% at 3 months.
July 27, 2023 | 1:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma's successful Phase 3 trials for UGN-102 could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. The successful Phase 3 trials for UGN-102, a treatment for bladder cancer, could therefore have a positive impact on UroGen Pharma's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100